Evaluation of affinity matured Affibody molecules for imaging of the immune checkpoint protein B7-H3; Nuclear Medicine and Biology; Vol. 124-125
| Parent link: | Nuclear Medicine and Biology.— .— Amsterdam: Elsevier Science Publishing Company Inc. Vol. 124-125.— 2023.— Article number 108384, 11 p. |
|---|---|
| Altres autors: | , , , , , , , , , , |
| Sumari: | Title screen B7-H3 (CD276), an immune checkpoint protein, is a promising molecular target for immune therapy of malignant tumours. Sufficient B7-H3 expression level is a precondition for successful therapy. Radionuclide molecular imaging is a powerful technique for visualization of expression levels of molecular targets in vivo. Use of small radiolabelled targeting proteins would enable high-contrast radionuclide imaging of molecular targets if adequate binding affinity and specificity of an imaging probe could be provided. Affibody molecules, small engineered affinity proteins based on a non-immunoglobulin scaffold, have demonstrated an appreciable potential in radionuclide imaging. Proof-of principle of radionuclide visualization of expression levels of B7-H3 in vivo was demonstrated using the [99mTc]Tc-AC12-GGGC Affibody molecule. We performed an affinity maturation of AC12, enabling selection of clones with higher affinity. Three most promising clones were expressed with a –GGGC (triglycine-cysteine) chelating sequence at the C-terminus and labelled with technetium-99m (99mTc). 99mTc-labelled conjugates bound to B7-H3-expressing cells specifically in vitro and in vivo. Biodistribution in mice bearing B7-H3-expressing SKOV-3 xenografts demonstrated improved imaging properties of the new conjugates compared with the parental variant [99mTc]Tc-AC12-GGGC. [99mTc]Tc-SYNT-179 provided the strongest improvement of tumour-to-organ ratios. Thus, affinity maturation of B7-H3 Affibody molecules could improve biodistribution and targeting properties for imaging of B7-H3-expressing tumours Текстовый файл AM_Agreement |
| Idioma: | anglès |
| Publicat: |
2023
|
| Matèries: | |
| Accés en línia: | https://doi.org/10.1016/j.nucmedbio.2023.108384 |
| Format: | Electrònic Capítol de llibre |
| KOHA link: | https://koha.lib.tpu.ru/cgi-bin/koha/opac-detail.pl?biblionumber=683368 |
MARC
| LEADER | 00000naa0a2200000 4500 | ||
|---|---|---|---|
| 001 | 683368 | ||
| 005 | 20251124140002.0 | ||
| 090 | |a 683368 | ||
| 100 | |a 20251124d2023 k||y0rusy50 ba | ||
| 101 | 0 | |a eng | |
| 102 | |a NL | ||
| 135 | |a drcn ---uucaa | ||
| 181 | 0 | |a i |b e | |
| 182 | 0 | |a b | |
| 183 | 0 | |a cr |2 RDAcarrier | |
| 200 | 1 | |a Evaluation of affinity matured Affibody molecules for imaging of the immune checkpoint protein B7-H3 |f Maryam Oroujeni, Ekaterina A. Bezverkhniaia, Tianqi Xu [et al.] | |
| 203 | |a Текст |b визуальный |c электронный | ||
| 283 | |a online_resource |2 RDAcarrier | ||
| 300 | |a Title screen | ||
| 320 | |a References: 64 tit | ||
| 330 | |a B7-H3 (CD276), an immune checkpoint protein, is a promising molecular target for immune therapy of malignant tumours. Sufficient B7-H3 expression level is a precondition for successful therapy. Radionuclide molecular imaging is a powerful technique for visualization of expression levels of molecular targets in vivo. Use of small radiolabelled targeting proteins would enable high-contrast radionuclide imaging of molecular targets if adequate binding affinity and specificity of an imaging probe could be provided. Affibody molecules, small engineered affinity proteins based on a non-immunoglobulin scaffold, have demonstrated an appreciable potential in radionuclide imaging. Proof-of principle of radionuclide visualization of expression levels of B7-H3 in vivo was demonstrated using the [99mTc]Tc-AC12-GGGC Affibody molecule. We performed an affinity maturation of AC12, enabling selection of clones with higher affinity. Three most promising clones were expressed with a –GGGC (triglycine-cysteine) chelating sequence at the C-terminus and labelled with technetium-99m (99mTc). 99mTc-labelled conjugates bound to B7-H3-expressing cells specifically in vitro and in vivo. Biodistribution in mice bearing B7-H3-expressing SKOV-3 xenografts demonstrated improved imaging properties of the new conjugates compared with the parental variant [99mTc]Tc-AC12-GGGC. [99mTc]Tc-SYNT-179 provided the strongest improvement of tumour-to-organ ratios. Thus, affinity maturation of B7-H3 Affibody molecules could improve biodistribution and targeting properties for imaging of B7-H3-expressing tumours | ||
| 336 | |a Текстовый файл | ||
| 371 | 0 | |a AM_Agreement | |
| 461 | 1 | |t Nuclear Medicine and Biology |c Amsterdam |n Elsevier Science Publishing Company Inc. | |
| 463 | 1 | |t Vol. 124-125 |v Article number 108384, 11 p. |d 2023 | |
| 610 | 1 | |a B7-H3 | |
| 610 | 1 | |a Affibody molecule | |
| 610 | 1 | |a Affinity maturation | |
| 610 | 1 | |a Peptide-based cysteine-containing chelator | |
| 610 | 1 | |a –GGGC | |
| 610 | 1 | |a AC12-GGGC | |
| 610 | 1 | |a Technetium-99m (99mTc) | |
| 610 | 1 | |a SKOV-3 xenograft | |
| 610 | 1 | |a SPECT/CT imaging | |
| 610 | 1 | |a электронный ресурс | |
| 610 | 1 | |a труды учёных ТПУ | |
| 701 | 1 | |a Oroujeni |b M. |g Maryam | |
| 701 | 1 | |a Bezverkhniaia |b E. A. |c pharmacist |c Research Engineer Tomsk Polytechnic University |f 1994- |g Ekaterina Aleksandrovna |9 22467 | |
| 701 | 0 | |a Xu Tianqi | |
| 701 | 0 | |a Liu Yongsheng | |
| 701 | 1 | |a Plotnikov |b E. V. |c chemist |c Associate Professor of Tomsk Polytechnic University, Candidate of Chemical Sciences |f 1983- |g Evgeny Vladimirovich |9 16417 | |
| 701 | 1 | |a Klint |b S. |g Susanne | |
| 701 | 1 | |a Ryer |b E. |g Eva | |
| 701 | 1 | |a Karlberg |b I. |g Ida | |
| 701 | 1 | |a Orlova |b A. M. |c specialist in the field of medical technology |c Senior Researcher, Oncoteranostika Research Center, Tomsk Polytechnic University, Ph.D |f 1960- |g Anna Markovna |9 22212 | |
| 701 | 1 | |a Frejd |b F. Y. |g Fredrik | |
| 701 | 1 | |a Tolmachev |b V. M. |c specialist in the field of medical technology |c Director of the Research Center "Oncoteranostika", Tomsk Polytechnic University, Ph.D |f 1961- |g Vladimir Maksimilianovich |9 22210 | |
| 801 | 0 | |a RU |b 63413507 |c 20251124 | |
| 850 | |a 63413507 | ||
| 856 | 4 | |u https://doi.org/10.1016/j.nucmedbio.2023.108384 |z https://doi.org/10.1016/j.nucmedbio.2023.108384 | |
| 942 | |c CF | ||